Vascular Endothelial Growth Factor Receptor

From Proteopedia

Jump to: navigation, search

Human VEGFR kinase domain complex with anti tumor inhibitor and sulfate (PDB code 3c7q)

  Export Animated Image

3D Structures of VEGFR

Updated on 16-January-2017

Additional Resources

For additional information, see:

References

  1. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006 May;7(5):359-71. PMID:16633338 doi:10.1038/nrm1911
  2. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007 Oct;19(10):2003-12. Epub 2007 Jun 12. PMID:17658244 doi:10.1016/j.cellsig.2007.05.013
  3. Gallina P, Nohra G, Cioloca C, Meder JF, Roux FX. [Multiple cavernoma of delayed appearance] Neurochirurgie. 1994;40(5):322-5. PMID:7596453
  4. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem. 1998 Nov 20;273(47):31283-8. PMID:9813036
  5. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol Biol. 2007 Mar;14(3):249-50. Epub 2007 Feb 11. PMID:17293873 doi:10.1038/nsmb1202
  6. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A, Claesson-Welsh L. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 2005 Jul 6;24(13):2342-53. Epub 2005 Jun 16. PMID:15962004 doi:10.1038/sj.emboj.7600709
  7. Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem. 1999 Mar 5;274(10):6453-60. PMID:10037737
  8. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795-803. PMID:12360282 doi:10.1038/nrc909
  9. Rosa DD, Ismael G, Lago LD, Awada A. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat Rev. 2008 Feb;34(1):61-80. Epub 2007 Sep 10. PMID:17826917 doi:10.1016/j.ctrv.2007.07.019
  10. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001 Sep;7(9):987-9. PMID:11533692 doi:10.1038/nm0901-987

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Michal Harel, Joel L. Sussman, Jaime Prilusky, Wayne Decatur, Alexander Berchansky

Personal tools